169 related articles for article (PubMed ID: 15998554)
1. Effect of adjuvant on reactogenicity and long-term immunogenicity of the malaria Vaccine ICC-1132 in macaques.
Langermans JA; Schmidt A; Vervenne RA; Birkett AJ; Calvo-Calle JM; Hensmann M; Thornton GB; Dubovsky F; Weiler H; Nardin E; Thomas AW
Vaccine; 2005 Sep; 23(41):4935-43. PubMed ID: 15998554
[TBL] [Abstract][Full Text] [Related]
2. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial.
Oliveira GA; Wetzel K; Calvo-Calle JM; Nussenzweig R; Schmidt A; Birkett A; Dubovsky F; Tierney E; Gleiter CH; Boehmer G; Luty AJ; Ramharter M; Thornton GB; Kremsner PG; Nardin EH
Infect Immun; 2005 Jun; 73(6):3587-97. PubMed ID: 15908388
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to Plasmodium falciparum MSP2 long synthetic peptides in mice.
Mata E; Carcaboso AM; Hernández RM; Igartua M; Corradin G; Pedraz JL
Vaccine; 2007 Jan; 25(5):877-85. PubMed ID: 17070628
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of multi-antigen AMA1-based vaccines formulated with CoVaccine HT™ and Montanide ISA 51 in rhesus macaques.
Kusi KA; Remarque EJ; Riasat V; Walraven V; Thomas AW; Faber BW; Kocken CH
Malar J; 2011 Jul; 10():182. PubMed ID: 21726452
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02.
Roestenberg M; Remarque E; de Jonge E; Hermsen R; Blythman H; Leroy O; Imoukhuede E; Jepsen S; Ofori-Anyinam O; Faber B; Kocken CH; Arnold M; Walraven V; Teelen K; Roeffen W; de Mast Q; Ballou WR; Cohen J; Dubois MC; Ascarateil S; van der Ven A; Thomas A; Sauerwein R
PLoS One; 2008; 3(12):e3960. PubMed ID: 19093004
[TBL] [Abstract][Full Text] [Related]
6. Stability and potency of the Plasmodium falciparum MSP1-19/AMA-1(III) chimeric vaccine candidate with Montanide ISA720 adjuvant.
Xue X; Ding F; Zhang Q; Pan X; Qu L; Pan W
Vaccine; 2010 Apr; 28(18):3152-8. PubMed ID: 20197139
[TBL] [Abstract][Full Text] [Related]
7. A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant.
Saul A; Lawrence G; Allworth A; Elliott S; Anderson K; Rzepczyk C; Martin LB; Taylor D; Eisen DP; Irving DO; Pye D; Crewther PE; Hodder AN; Murphy VJ; Anders RF
Vaccine; 2005 Apr; 23(23):3076-83. PubMed ID: 15811655
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice.
Devi YS; Mukherjee P; Yazdani SS; Shakri AR; Mazumdar S; Pandey S; Chitnis CE; Chauhan VS
Vaccine; 2007 Jul; 25(28):5166-74. PubMed ID: 17544179
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults.
Pierce MA; Ellis RD; Martin LB; Malkin E; Tierney E; Miura K; Fay MP; Marjason J; Elliott SL; Mullen GED; Rausch K; Zhu D; Long CA; Miller LH
Vaccine; 2010 Mar; 28(10):2236-2242. PubMed ID: 20051276
[TBL] [Abstract][Full Text] [Related]
10. Preclinical assessment of the receptor-binding domain of Plasmodium vivax Duffy-binding protein as a vaccine candidate in rhesus macaques.
Moreno A; Caro-Aguilar I; Yazdani SS; Shakri AR; Lapp S; Strobert E; McClure H; Chitnis CE; Galinski MR
Vaccine; 2008 Aug; 26(34):4338-44. PubMed ID: 18573299
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of an alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of Plasmodium falciparum circumsporozoite protein.
Gregson AL; Oliveira G; Othoro C; Calvo-Calle JM; Thorton GB; Nardin E; Edelman R
PLoS One; 2008 Feb; 3(2):e1556. PubMed ID: 18253503
[TBL] [Abstract][Full Text] [Related]
12. Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A.
Stewart VA; McGrath SM; Walsh DS; Davis S; Hess AS; Ware LA; Kester KE; Cummings JF; Burge JR; Voss G; Delchambre M; Garçon N; Tang DB; Cohen JD; Heppner DG
Vaccine; 2006 Oct; 24(42-43):6483-92. PubMed ID: 16904798
[TBL] [Abstract][Full Text] [Related]
13. Long-lasting protective immune response to the 19-kilodalton carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 in mice.
Jeamwattanalert P; Mahakunkijcharoen Y; Kittigul L; Mahannop P; Pichyangkul S; Hirunpetcharat C
Clin Vaccine Immunol; 2007 Apr; 14(4):342-7. PubMed ID: 17314232
[TBL] [Abstract][Full Text] [Related]
14. Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations.
Miles AP; McClellan HA; Rausch KM; Zhu D; Whitmore MD; Singh S; Martin LB; Wu Y; Giersing BK; Stowers AW; Long CA; Saul A
Vaccine; 2005 Mar; 23(19):2530-9. PubMed ID: 15752840
[TBL] [Abstract][Full Text] [Related]
15. Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175.
Chitnis CE; Mukherjee P; Mehta S; Yazdani SS; Dhawan S; Shakri AR; Bhardwaj R; Gupta PK; Hans D; Mazumdar S; Singh B; Kumar S; Pandey G; Parulekar V; Imbault N; Shivyogi P; Godbole G; Mohan K; Leroy O; Singh K; Chauhan VS
PLoS One; 2015; 10(4):e0117820. PubMed ID: 25927360
[TBL] [Abstract][Full Text] [Related]
16. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.
Polhemus ME; Magill AJ; Cummings JF; Kester KE; Ockenhouse CF; Lanar DE; Dutta S; Barbosa A; Soisson L; Diggs CL; Robinson SA; Haynes JD; Stewart VA; Ware LA; Brando C; Krzych U; Bowden RA; Cohen JD; Dubois MC; Ofori-Anyinam O; De-Kock E; Ballou WR; Heppner DG
Vaccine; 2007 May; 25(21):4203-12. PubMed ID: 17442466
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and in vitro protective efficacy of a polyepitope Plasmodium falciparum candidate vaccine constructed by epitope shuffling.
Cai Q; Peng G; Bu L; Lin Y; Zhang L; Lustigmen S; Wang H
Vaccine; 2007 Jul; 25(28):5155-65. PubMed ID: 17548134
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations.
Tamborrini M; Stoffel SA; Westerfeld N; Amacker M; Theisen M; Zurbriggen R; Pluschke G
Malar J; 2011 Dec; 10():359. PubMed ID: 22166048
[TBL] [Abstract][Full Text] [Related]
19. Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial.
Hermsen CC; Verhage DF; Telgt DS; Teelen K; Bousema JT; Roestenberg M; Bolad A; Berzins K; Corradin G; Leroy O; Theisen M; Sauerwein RW
Vaccine; 2007 Apr; 25(15):2930-40. PubMed ID: 16914240
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of a chimeric malaria vaccine candidate in Montanide ISA 720: immunogenicity and safety in rhesus macaques.
Langermans JA; Hensmann M; van Gijlswiik M; Zhang D; Pan W; Giersing BK; Locke E; Dubovsk F; Wittes J; Thomas AW
Hum Vaccin; 2006; 2(5):222-6. PubMed ID: 17035731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
